Cytokinetics | CYTK - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Amgen USD 4.61B 777M 2026-06
Arca Biopharma USD -36.43M 2M 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD -243.8M 758.1M 2026-06
Brainstorm Cell Therapeutics USD -2.05M 198K 2026-03
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Capricor Therapeutics USD -29.16M 2.87M 2025-12
Cytokinetics USD -179.17M 2.05M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 251.34M 15.43M 2026-03
Geron USD -236K 10.55M 2026-03
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
Merck USD 840M 2.72B 2026-06
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.38B 449M 2026-06